MARK2 and hepatocellular carcinoma: Under the context of hepatocellular carcinoma, circZFR promotes hepatocellular carcinoma development by inhibiting the STAT3/NF-κB pathway [170]; circLIFR promotes cell proliferation by interacting with TANK binding kinase 1 (TBK1), which is a serine/threonine kinase that regulates NF-κB pathway [171]; circCORO1C promotes hepatocellular carcinoma proliferation and metastasis via upregulating NF-κB pathway induced PD-L1 expression [172].